CA2994089A1
(en)
|
2002-11-18 |
2004-06-03 |
Roche Innovation Center Copenhagen A/S |
Antisense gapmer oligonucleotides
|
US7399853B2
(en)
|
2003-04-28 |
2008-07-15 |
Isis Pharmaceuticals |
Modulation of glucagon receptor expression
|
US8815599B2
(en)
|
2004-06-01 |
2014-08-26 |
Pronai Therapeutics, Inc. |
Methods and compositions for the inhibition of gene expression
|
US7807647B2
(en)
*
|
2004-06-01 |
2010-10-05 |
Pronai Therapeutics, Inc. |
Methods and compositions for cancer therapy
|
US20050287667A1
(en)
*
|
2004-06-01 |
2005-12-29 |
Pronai Therapeutics, Inc. |
Methods and compositions for the inhibition of gene expression
|
WO2007035759A1
(en)
*
|
2005-09-19 |
2007-03-29 |
Johnson & Johnson Pharmaceutical Research & Development L.L.C. |
Modulation of glucocorticoid receptor expression
|
US20070087987A1
(en)
*
|
2005-09-19 |
2007-04-19 |
Monia Brett P |
Modulation of glucagon receptor expression
|
US8367628B2
(en)
|
2005-12-01 |
2013-02-05 |
Pronai Therapeutics, Inc. |
Amphoteric liposome formulation
|
WO2007064853A2
(en)
*
|
2005-12-01 |
2007-06-07 |
Pronai Therapeutics, Inc. |
Locked nucleic acid oligonucleotides
|
WO2007064945A2
(en)
|
2005-12-01 |
2007-06-07 |
Pronai Therapeutics, Inc. |
Cancer therapies and pharmaceutical compositions used therein
|
US8288354B2
(en)
|
2005-12-28 |
2012-10-16 |
The Scripps Research Institute |
Natural antisense and non-coding RNA transcripts as drug targets
|
AU2012216487B2
(en)
*
|
2006-04-03 |
2015-05-14 |
Roche Innovation Center Copenhagen A/S |
Pharmaceutical composition comprising anti-miRNA antisense oligonucleotides
|
CA2649045C
(en)
*
|
2006-04-03 |
2019-06-11 |
Santaris Pharma A/S |
Pharmaceutical composition comprising anti-mirna antisense oligonucleotides
|
ES2569558T3
(es)
|
2006-04-03 |
2016-05-11 |
Roche Innovation Center Copenhagen A/S |
Composición farmacéutica que comprende oligonucleótidos antisentido anti-ARNmi
|
JP5825754B2
(ja)
*
|
2006-05-05 |
2015-12-02 |
アイシス ファーマシューティカルズ, インコーポレーテッド |
Apobの発現を調節するための化合物および方法
|
US20090023221A1
(en)
*
|
2006-05-19 |
2009-01-22 |
Exigon A/S |
Oligonucleotide probes useful for detection and analysis of microrna precursors
|
DK2410053T4
(da)
|
2006-10-18 |
2020-08-31 |
Ionis Pharmaceuticals Inc |
Antisense-forbindelser
|
DK2149605T3
(da)
|
2007-03-22 |
2013-09-30 |
Santaris Pharma As |
Korte RNA antagonist forbindelser til modulering af det ønskede mRNA
|
CA2681406A1
(en)
|
2007-03-22 |
2008-09-25 |
Santaris Pharma A/S |
Rna antagonist compounds for the inhibition of apo-b100 expression
|
DK2195428T3
(en)
|
2007-09-19 |
2014-03-03 |
Applied Biosystems Llc |
SIRNA SEQUENCE-INDEPENDENT MODIFICATION FORMS TO REDUCE TARGET-FAILING PHENOTYPIC EFFECTS OF RNAI, AND STABILIZED FORMS THEREOF
|
WO2009043353A2
(en)
|
2007-10-04 |
2009-04-09 |
Santaris Pharma A/S |
Micromirs
|
KR20100110298A
(ko)
*
|
2007-11-26 |
2010-10-12 |
산타리스 팔마 에이/에스 |
안드로겐 수용체를 표적화하는 lna 길항제
|
WO2009071681A2
(en)
*
|
2007-12-07 |
2009-06-11 |
Santaris Pharma A/S |
Rna antagonist compounds for the modulation of bcl-2
|
AU2009221064B2
(en)
|
2008-03-07 |
2014-12-11 |
Roche Innovation Center Copenhagen A/S |
Pharmaceutical compositions for treatment of microRNA related diseases
|
ES2541442T3
(es)
|
2008-08-01 |
2015-07-20 |
Roche Innovation Center Copenhagen A/S |
Modulación mediada por microARN de factores estimulantes de colonias
|
EP2352830B1
(de)
|
2008-10-03 |
2019-01-16 |
CuRNA, Inc. |
Behandlung von krankheiten in verbindung mit apolipoprotein a1 durch hemmung eines natürlichen antisense-transkripts gegen apolipoprotein a1
|
JP6049260B2
(ja)
*
|
2008-10-10 |
2016-12-21 |
ダナ ファーバー キャンサー インスティテュート インコーポレイテッド |
プロアポトーシスbax及びbcl−2ポリペプチドの化学モジュレータ
|
WO2010043582A1
(en)
*
|
2008-10-17 |
2010-04-22 |
Santaris Pharma A/S |
Method for the treatment of cancer
|
ES2600781T3
(es)
|
2008-12-04 |
2017-02-10 |
Curna, Inc. |
Tratamiento para enfermedades relacionadas con el factor de crecimiento del endotelio vascular (vegf) mediante la inhibición de transcritos antisentido naturales de vegf
|
EP2370582B1
(de)
|
2008-12-04 |
2017-05-10 |
CuRNA, Inc. |
Behandlung von tumorsuppressorgen-bedingten erkrankungen mittels hemmung des natürlichen antisense-transkripts gegen das gen
|
WO2010065792A2
(en)
|
2008-12-04 |
2010-06-10 |
Curna, Inc. |
Treatment of erythropoietin (epo) related diseases by inhibition of natural antisense transcript to epo
|
ES2762610T3
(es)
|
2009-02-12 |
2020-05-25 |
Curna Inc |
Tratamiento de enfermedades relacionadas con el factor neurotrófico derivado de cerebro (BDNF) por inhibición de transcrito antisentido natural para BDNF
|
US9464287B2
(en)
|
2009-03-16 |
2016-10-11 |
Curna, Inc. |
Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
|
CN102549159B
(zh)
|
2009-03-17 |
2016-08-10 |
库尔纳公司 |
通过抑制针对δ样1同源物(DLK1)的天然反义转录物来治疗DLK1相关的疾病
|
EP2421970B1
(de)
|
2009-04-24 |
2016-09-07 |
Roche Innovation Center Copenhagen A/S |
Pharmazeutische zusammensetzungen zur behandlung von nicht auf interferon ansprechende hcv-patienten
|
CN102803492B
(zh)
|
2009-05-06 |
2016-06-29 |
库尔纳公司 |
通过抑制针对三重四脯氨酸(ttp)的天然反义转录物来治疗ttp相关疾病
|
CN103223177B
(zh)
|
2009-05-06 |
2016-08-10 |
库尔纳公司 |
通过针对脂质转运和代谢基因的天然反义转录物的抑制治疗脂质转运和代谢基因相关疾病
|
CA3185821A1
(en)
|
2009-05-08 |
2010-11-11 |
Curna, Inc. |
Treatment of dystrophin family related diseases by inhibition of natural antisense transcript to dmd family
|
EP2432881B1
(de)
|
2009-05-18 |
2017-11-15 |
CuRNA, Inc. |
Behandlung von krankheiten im zusammenhang mit dem reprogrammierungsfaktor durch hemmung des natürlichen antisense-transkripts zu einem reprogrammierungsfaktor
|
CA2762987A1
(en)
|
2009-05-22 |
2010-11-25 |
Joseph Collard |
Treatment of transcription factor e3 (tfe3) and insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to tfe3
|
JP5960049B2
(ja)
|
2009-05-28 |
2016-08-02 |
クルナ・インコーポレーテッド |
抗ウイルス遺伝子に対する天然アンチセンス転写物の抑制による抗ウイルス遺伝子関連疾患の治療
|
JP6128846B2
(ja)
|
2009-06-16 |
2017-05-17 |
クルナ・インコーポレーテッド |
パラオキソナーゼ(pon1)に対する天然アンチセンス転写物の抑制によるpon1遺伝子関連疾患の治療
|
US20120171170A1
(en)
|
2009-06-16 |
2012-07-05 |
Opko Curna, Llc |
Treatment of collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
|
EP2446036B1
(de)
|
2009-06-24 |
2017-03-01 |
CuRNA, Inc. |
Behandlung von erkrankungen im zusammenhang mit tumornekrose faktor-rezeptor 2 (tnfr2) mittels hemmung des natürlichen antisense-transkripts gegen tnfr2
|
CN102482672B
(zh)
|
2009-06-26 |
2016-11-09 |
库尔纳公司 |
通过抑制唐氏综合征基因的天然反义转录物治疗唐氏综合征基因相关疾病
|
EP2456870A1
(de)
|
2009-07-21 |
2012-05-30 |
Santaris Pharma A/S |
Auf pcsk9 gerichtete antisense-oligomere
|
JP2013500017A
(ja)
|
2009-07-24 |
2013-01-07 |
カッパーアールエヌエー,インコーポレイテッド |
サ−チュイン(sirt)への天然アンチセンス転写物の阻止によるサ−チュイン(sirt)関連疾患の治療
|
CN102762731B
(zh)
|
2009-08-05 |
2018-06-22 |
库尔纳公司 |
通过抑制针对胰岛素基因(ins)的天然反义转录物来治疗胰岛素基因(ins)相关的疾病
|
US9044493B2
(en)
|
2009-08-11 |
2015-06-02 |
Curna, Inc. |
Treatment of Adiponectin related diseases by inhibition of natural antisense transcript to an Adiponectin
|
WO2011022606A2
(en)
|
2009-08-21 |
2011-02-24 |
Curna, Inc. |
Treatment of 'c terminus of hsp70-interacting protein' (chip) related diseases by inhibition of natural antisense transcript to chip
|
WO2011031482A2
(en)
|
2009-08-25 |
2011-03-17 |
Curna, Inc. |
Treatment of 'iq motif containing gtpase activating protein' (iqgap) related diseases by inhibition of natural antisense transcript to iqgap
|
EP2480669B1
(de)
|
2009-09-25 |
2017-11-08 |
CuRNA, Inc. |
Behandlung filaggrin (flg)-assoziierter erkrankungen durch modulierung der flg-expression und -aktivität
|
RU2639550C2
(ru)
|
2009-12-16 |
2017-12-21 |
Курна, Инк. |
Лечение заболеваний, связанных с сайт-1 мембраносвязанной пептидазой транскрипционных факторов (mbtps1), путем ингибирования природного антисмыслового транскрипта к mbtps1
|
CN102781480B
(zh)
|
2009-12-23 |
2018-07-27 |
库尔纳公司 |
通过抑制解偶联蛋白2(ucp2)的天然反义转录物而治疗ucp2相关疾病
|
KR101891352B1
(ko)
|
2009-12-23 |
2018-08-24 |
큐알엔에이, 인크. |
간세포 성장 인자(hgf)에 대한 천연 안티센스 전사체의 억제에 의한 hgf 관련 질환의 치료
|
CA2785173A1
(en)
|
2009-12-29 |
2011-07-28 |
Curna, Inc. |
Treatment of nuclear respiratory factor 1 (nrf1) related diseases by inhibition of natural antisense transcript to nrf1
|
WO2011090741A2
(en)
|
2009-12-29 |
2011-07-28 |
Opko Curna, Llc |
TREATMENT OF TUMOR PROTEIN 63 (p63) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO p63
|
US20120289583A1
(en)
|
2009-12-31 |
2012-11-15 |
Curna, Inc. |
Treatment of insulin receptor substrate 2 (irs2) related diseases by inhibition of natural antisense transcript to irs2 and transcription factor e3 (tfe3)
|
US8946181B2
(en)
|
2010-01-04 |
2015-02-03 |
Curna, Inc. |
Treatment of interferon regulatory factor 8 (IRF8) related diseases by inhibition of natural antisense transcript to IRF8
|
EP2521785B1
(de)
|
2010-01-06 |
2022-03-09 |
CuRNA, Inc. |
Inhibition des natürlichen antisense-transkripts des pankreasentwicklungsgens zur verwendung in der behandlung von pankreatischen entwicklungsgenbezogenen krankheiten
|
US9200277B2
(en)
|
2010-01-11 |
2015-12-01 |
Curna, Inc. |
Treatment of sex hormone binding globulin (SHBG) related diseases by inhibition of natural antisense transcript to SHBG
|
CA2786568A1
(en)
|
2010-01-25 |
2011-07-28 |
Curna, Inc. |
Treatment of rnase h1 related diseases by inhibition of natural antisense transcript to rnase h1
|
JP5976548B2
(ja)
|
2010-02-22 |
2016-08-23 |
カッパーアールエヌエー,インコーポレイテッド |
Pycr1に対する天然アンチセンス転写物の阻害によるピロリン−5−カルボン酸レダクターゼ1(pycr1)関連疾患の治療
|
CA2795145C
(en)
|
2010-04-02 |
2019-01-22 |
Curna, Inc. |
Treatment of colony-stimulating factor 3 (csf3) related diseases by inhibition of natural antisense transcript to csf3
|
CA2795281A1
(en)
|
2010-04-09 |
2011-10-13 |
Curna, Inc. |
Treatment of fibroblast growth factor 21 (fgf21) related diseases by inhibition of natural antisense transcript to fgf21
|
RU2693462C2
(ru)
|
2010-05-03 |
2019-07-03 |
Курна, Инк. |
Лечение заболеваний, связанных с сиртуином (sirt), путем ингибирования природного антисмыслового транскрипта к сиртуину (sirt)
|
TWI531370B
(zh)
|
2010-05-14 |
2016-05-01 |
可娜公司 |
藉由抑制par4天然反股轉錄本治療par4相關疾病
|
RU2585229C2
(ru)
|
2010-05-26 |
2016-05-27 |
Курна, Инк. |
Лечение заболеваний, связанных с атональным гомологом 1 (атон1), путем ингибирования природного антисмыслового транскрипта гена атон1
|
JP5917497B2
(ja)
|
2010-05-26 |
2016-05-18 |
カッパーアールエヌエー,インコーポレイテッド |
メチオニンスルホキシドレダクターゼa(msra)に対する天然アンチセンス転写物の阻害によるmsra関連疾患の治療
|
DK2585596T3
(da)
|
2010-06-23 |
2021-04-06 |
Curna Inc |
Behandling af spændingsreguleret natriumkanal-alpha-underenhed (scna)-relaterede sygdomme ved inhibering af naturligt antisense-transkript til scna
|
JP5998131B2
(ja)
|
2010-07-14 |
2016-09-28 |
カッパーアールエヌエー,インコーポレイテッド |
Discslargehomolog(dlg)dlg1への天然アンチセンス転写物の阻害によるdlg関連疾患の治療
|
EP2625274B1
(de)
|
2010-10-06 |
2017-07-19 |
CuRNA, Inc. |
Behandlung sialidase-4-(neu4)-vermittelter erkrankungen durch hemmung des natürlichen antisense-transkripts gegen neu4
|
US9222088B2
(en)
|
2010-10-22 |
2015-12-29 |
Curna, Inc. |
Treatment of alpha-L-iduronidase (IDUA) related diseases by inhibition of natural antisense transcript to IDUA
|
US10000752B2
(en)
|
2010-11-18 |
2018-06-19 |
Curna, Inc. |
Antagonat compositions and methods of use
|
RU2608493C2
(ru)
|
2010-11-23 |
2017-01-18 |
Курна, Инк. |
Лечение заболеваний, связанных с nanog, путем ингибирования природного антисмыслового транскрипта nanog
|
EP3467109A1
(de)
|
2011-02-08 |
2019-04-10 |
Ionis Pharmaceuticals, Inc. |
Oligomere verbindungen mit bicyclischen nukleotiden und verwendungen davon
|
TWI678375B
(zh)
|
2011-06-09 |
2019-12-01 |
可娜公司 |
藉由抑制共濟蛋白(frataxin,fxn)之天然反股轉錄本治療fxn相關疾病
|
EP4269584A3
(de)
|
2011-08-11 |
2024-03-27 |
Ionis Pharmaceuticals, Inc. |
Selektive antisense-verbindungen und verwendungen davon
|
CN103874486A
(zh)
|
2011-09-06 |
2014-06-18 |
库尔纳公司 |
用小分子治疗与电压门控钠通道的α亚基(SCNxA)相关的疾病
|
EP2756080B1
(de)
*
|
2011-09-14 |
2019-02-20 |
Translate Bio MA, Inc. |
Multimere oligonukleotidverbindungen
|
JP6092226B2
(ja)
|
2011-09-20 |
2017-03-08 |
アイオーニス ファーマシューティカルズ, インコーポレーテッドIonis Pharmaceuticals,Inc. |
Gcgr発現のアンチセンス調整
|
AU2012322788B2
(en)
|
2011-10-11 |
2018-01-04 |
The Brigham And Women's Hospital, Inc. |
Micrornas in neurodegenerative disorders
|
AU2012328680A1
(en)
|
2011-10-25 |
2014-05-01 |
Ionis Pharmaceuticals, Inc. |
Antisense modulation of GCCR expression
|
CA2855362A1
(en)
*
|
2011-11-11 |
2013-05-16 |
Santaris Pharma A/S |
Compounds for the modulation of beta-catenin expression and uses thereof
|
HUE040179T2
(hu)
|
2012-03-15 |
2019-02-28 |
Curna Inc |
Agyi eredetû neutrotróf faktorral (Brain-derived neurotrophic factor, BDNF) összefüggõ betegségek kezelése a BDNF-fel kapcsolatos természetes antiszensz transzkriptumok gátlása révén
|
WO2013159108A2
(en)
|
2012-04-20 |
2013-10-24 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds comprising bicyclic nucleotides and uses thereof
|
DK2850186T3
(en)
|
2012-05-16 |
2019-04-08 |
Translate Bio Ma Inc |
COMPOSITIONS AND PROCEDURES FOR MODULATING SMN GENFAMILY EXPRESSION
|
WO2013173598A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating atp2a2 expression
|
JP2015518710A
(ja)
|
2012-05-16 |
2015-07-06 |
ラナ セラピューティクス インコーポレイテッド |
ヘモグロビン遺伝子ファミリー発現を調節するための組成物及び方法
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
KR20160074368A
(ko)
|
2012-05-16 |
2016-06-28 |
라나 테라퓨틱스, 인크. |
Utrn 발현을 조절하기 위한 조성물 및 방법
|
WO2013173608A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating mecp2 expression
|
CN102827056B
(zh)
*
|
2012-09-03 |
2014-07-23 |
华东理工大学 |
N-芳基取代吡咯烷酮衍生物及其用途
|
JP2015529469A
(ja)
*
|
2012-09-14 |
2015-10-08 |
ラナ セラピューティクス インコーポレイテッド |
多量体オリゴヌクレオチド化合物
|
AU2013324716B2
(en)
*
|
2012-09-26 |
2019-06-13 |
Guandong Mijinjia Biotechnology Co., Ltd |
Oligomers with improved off-target profile
|
EP2906699A4
(de)
|
2012-10-11 |
2016-06-08 |
Ionis Pharmaceuticals Inc |
Oligomere verbindungen mit bicyclischen nukleosiden und verwendungen davon
|
JP2016509572A
(ja)
|
2012-11-05 |
2016-03-31 |
プロナイ セラピューティクス インコーポレイテッド |
Bcl2発現の調節による癌の処置のためにバイオマーカーを使用する方法
|
CA2889596C
(en)
|
2012-11-15 |
2022-08-23 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugates
|
SG11201505387PA
(en)
|
2013-01-30 |
2015-08-28 |
Hoffmann La Roche |
Lna oligonucleotide carbohydrate conjugates
|
EA201591590A1
(ru)
|
2013-03-27 |
2016-05-31 |
Исарна Терапьютикс Гмбх |
Модифицированные олигонуклеотиды трф-бета
|
TWI680767B
(zh)
|
2013-05-01 |
2020-01-01 |
美商雷格勒斯治療公司 |
用於增強的細胞攝取之化合物及方法
|
JP2016518842A
(ja)
|
2013-05-01 |
2016-06-30 |
レグルス セラピューティクス インコーポレイテッド |
マイクロRNA化合物およびmiR−122をモジュレートする方法
|
CA2915316C
(en)
|
2013-06-27 |
2024-01-02 |
Roche Innovation Center Copenhagen A/S |
Antisense oligomers and conjugates targeting pcsk9
|
CA2921457A1
(en)
*
|
2013-08-16 |
2015-02-19 |
Rana Therapeutics, Inc. |
Heterochromatin forming non-coding rnas
|
WO2015075166A1
(en)
|
2013-11-22 |
2015-05-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for treatment of a bacterial infection
|
WO2015118407A2
(en)
|
2014-01-29 |
2015-08-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Oligonucleotides and methods for inhibiting or reducing bacterial biofilms
|
JP6835826B2
(ja)
*
|
2015-08-24 |
2021-02-24 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Lna−gプロセス
|
EP3394258B1
(de)
|
2015-10-22 |
2021-09-22 |
Roche Innovation Center Copenhagen A/S |
Test für in-vitro-toxizitätsscreening
|
CN107574243B
(zh)
*
|
2016-06-30 |
2021-06-29 |
博奥生物集团有限公司 |
分子标志物、内参基因及其应用、检测试剂盒以及检测模型的构建方法
|
AU2017339561B2
(en)
|
2016-10-07 |
2024-02-01 |
Secarna Pharmaceuticals Gmbh & Co. Kg |
Novel approach for treating cancer
|
US11542294B2
(en)
|
2017-03-29 |
2023-01-03 |
Roche Innovation Center Copenhagen A/S |
Rapid unylinker cleavage
|
PT3669193T
(pt)
*
|
2017-08-18 |
2022-07-06 |
European Molecular Biology Laboratory |
Captura de interatoma de arn melhorada (eric)
|
US11261445B2
(en)
|
2017-10-17 |
2022-03-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Combination treatment for cystic fibrosis
|
WO2021005223A1
(en)
|
2019-07-10 |
2021-01-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the treatment of epilepsy
|
WO2021074657A1
(en)
|
2019-10-17 |
2021-04-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Combination treatment for cystic fibrosis
|
EP4061943A1
(de)
|
2019-11-19 |
2022-09-28 |
Institut National de la Santé et de la Recherche Médicale (INSERM) |
Antisense-oligonukleotide und deren verwendung zur behandlung von krebs
|
CN115996935A
(zh)
*
|
2020-07-09 |
2023-04-21 |
豪夫迈·罗氏有限公司 |
使用改进的氧化方案制备寡核苷酸的方法
|
WO2022011262A1
(en)
|
2020-07-10 |
2022-01-13 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Methods and compositions for treating epilepsy
|
WO2023152369A1
(en)
|
2022-02-14 |
2023-08-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Nucleic acid mir-9 inhibitor for the treatment of cystic fibrosis
|
WO2024017990A1
(en)
|
2022-07-21 |
2024-01-25 |
Institut National de la Santé et de la Recherche Médicale |
Methods and compositions for treating chronic pain disorders
|